Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3541860 · 2 trials · 2 indications
Cumulative number will be measured by magnetic resonance imaging (MRI) scans.
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3541860 Phase 2a Dose Level 1 | EXPERIMENTAL | LY3541860 will be given intravenously (IV) |
| LY3541860 Phase 2a Dose Level 2 | EXPERIMENTAL | LY3541860 will be given IV. |
| Placebo Phase 2a | PLACEBO_COMPARATOR | Placebo will be given IV. |
| LY3541860 Phase 2b Dose Level 3 | EXPERIMENTAL | LY3541860 will be given IV. |
| LY3541860 Phase 2b Dose Level 4 | EXPERIMENTAL | LY3541860 will be given IV. |
| Placebo Phase 2b | PLACEBO_COMPARATOR | Placebo will be given IV. |
| LY3541860 (Part A) | EXPERIMENTAL | Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC). |
| LY3541860 (Part B) | EXPERIMENTAL | Multiple doses of LY3541860 administered either IV or SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single doses of Placebo administered either IV or SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Multiple doses of Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3541860 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lu...
LY3541860 is an investigational small molecule being studied for use in healthy participants and in adults with relapsing multiple sclerosis. It is currently in clinical development and has not been approved by regulatory authorities.
LY3541860 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY.
LY3541860 is in clinical development. A Phase 1 study in healthy participants has been completed, and a Phase 2 study in adults with relapsing multiple sclerosis is active but not recruiting participants.
LY3541860 has been studied in two clinical trials. NCT05042310 was a completed Phase 1 study in healthy Japanese and non-Japanese participants. NCT06220669 is an active Phase 2 study in adults with relapsing multiple sclerosis.
Yes, LY3541860 is being studied in adults with relapsing multiple sclerosis in a Phase 2 clinical trial. The trial is active but not recruiting participants and is being conducted in the United States, France, Italy, Latvia, Poland, Slovakia, and the United Kingdom.